유도 AmpC β-lactamase를 생산하는 장내세균 혈액분리균에서의 extended-spectrum β-lactamase 생성균의 빈도
Prevalence of Extended-spectrum β-lactamase among Enterobacteriacae Blood Isolates with Inducible AmpC β-lactamase
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Among the inducible AmpC β-lactamase-producing members of the family Enterobacteriaceae such as Enterobacter spp., Citrobacter spp., Serratia spp.,and Morganella morganii (ECSM), the prevalence of ESBL-producing isolates are increasing. However, there have been only a limited number of studies that have investigated the prevalence for ESBL-production in blood isolates of these organisms. Materials and Methods: We performed a prospective observational study to evaluate the prevalence for ESBL production among ECSM blood isolates. All consecutive blood isolates in the Samsung Medical Center were included from Oct 2006 to Mar 2008. Antimicrobial susceptibility test was performed by broth microdilution method. ESBLs were confirmed by double-disk synergy test and ESBL phenotypes were determined by PCR. Results: The 124 isolates (94 Enterobacter spp., 18 Citrobacter spp., 8 Serratia spp. and 4 Morganella spp.) were investigated. Among 124 ESCM isolates, 30 isolates (24.2%) showed ESBL-producing activity. Derepressed or partially derepressed AmpC mutants and derepressed AmpC mutants with ESBL production accounted for 36.3% (45/124) and 16.9% (21/124), respectively. Of ESBL producers, the most prevalent ESBL was SHV-12 (5/24, 20.8%). Conclusions: The prevalence of ESBL-producing isolates is high in Enterobacter spp.,Serratia marcescens and Citrobacter spp. clinical isolates. It suggested that routine screening test for ESBLs among Enterobacteriacae blood isolates with inducible AmpC β-lactamase should be needed.
Abstract
Background: Among the inducible AmpC β-lactamase-producing members of the family Enterobacteriaceae such as Enterobacter spp., Citrobacter spp., Serratia spp.,and Morganella morganii (ECSM), the prevalence of ESBL-producing isolates are increasing. However, there have been only a limited number of studies that have investigated the prevalence for ESBL-production in blood isolates of these organisms. Materials and Methods: We performed a prospective observational study to evaluate the prevalence for ESBL production among ECSM blood isolates. All consecutive blood isolates in the Samsung Medical Center were included from Oct 2006 to Mar 2008. Antimicrobial susceptibility test was performed by broth microdilution method. ESBLs were confirmed by double-disk synergy test and ESBL phenotypes were determined by PCR. Results: The 124 isolates (94 Enterobacter spp., 18 Citrobacter spp., 8 Serratia spp. and 4 Morganella spp.) were investigated. Among 124 ESCM isolates, 30 isolates (24.2%) showed ESBL-producing activity. Derepressed or partially derepressed AmpC mutants and derepressed AmpC mutants with ESBL production accounted for 36.3% (45/124) and 16.9% (21/124), respectively. Of ESBL producers, the most prevalent ESBL was SHV-12 (5/24, 20.8%). Conclusions: The prevalence of ESBL-producing isolates is high in Enterobacter spp.,Serratia marcescens and Citrobacter spp. clinical isolates. It suggested that routine screening test for ESBLs among Enterobacteriacae blood isolates with inducible AmpC β-lactamase should be needed.
참고문헌 (16)
- Paterson DL, "Resistance in gram-negative bacteria: enterobacteriaceae", Am J Med, 119(Suppl 6), pp.S20~S28 (2006)
- Pfaller MA, "Overview of the epidemiological profile and laboratory detection of extended-spectrum beta-lactamases", Clin Infect Dis, 42(Suppl 4), pp.S153~S163 (2006)
- Choi SH, "Prevalence, microbiology, and clinical characteristics of extended-spectrum beta-lactamase-producing Enterobacter spp., Serratia marcescens , Citrobacter freundii , and Morganella morganii in Korea", Eur J Clin Microbiol Infect Dis, 26, pp.557~561 (2007)
- Kim J, "Prevalence of derepressed ampC mutants and extended-spectrum beta-lactamase producers among clinical isolates of Citrobacter freundii , Enterobacter spp., and Serratia marcescens in Korea: dissemination of CTX-M-3, TEM-52, and SHV-12", J Clin Microbiol, 43, pp.2452~2455 (2005)
- Pai H, "High prevalence of extended-spectrum beta-lactamase-producing strains among blood isolates of Enterobacter spp. collected in a tertiary hospital during an 8-year period and their antimicrobial susceptibility patterns", Antimicrob Agents Chemother, 48, pp.3159~3161 (2004)
- Park YJ, "Occurrence of extended-spectrum beta-lactamases among chromosomal AmpC-producing Enterobacter cloacae , Citrobacter freundii , and Serratia marcescens in Korea and investigation of screening criteria", Diagn Microbiol Infect Dis, 51, pp.265~269 (2005)
- Chow JW, "Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary", Int J Antimicrob Agents, 11, pp.7~12 (1999)
- Jacoby GA, "Detection of extended-spectrum betalactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli", J Clin Microbiol, 34, pp.908~911 (1996)
- Tzelepi E, "Detection of extended-spectrum beta-lactamases in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes", J Clin Microbiol, 38, pp.542~546 (2000)
- Livermore DM, "Detection of beta-lactamasemediated resistance", J Antimicrob Chemother, 48(Suppl 1), pp.59~64 (2001)
- Ko KS, "Prevalence and characterization of extendedspectrum beta-lactamase-producing Enterobacteriaceae isolated in Korean hospitals", Diagn Microbiol Infect Dis, 61, pp.453~459 (2008)
- Navon-Venezia S, "Occurrence and phenotypic characteristics of extended-spectrum beta-lactamases among members of the family Enterobacteriaceae at the Tel-Aviv Medical Center (Israel) and evaluation of diagnostic tests", J Clin Microbiol, 41, pp.155~158 (2003)
- Bell JM, "Prevalence of extended-spectrum beta-lactamaseproducing Enterobacter cloacae in the Asia-Pacific region: results from the SENTRY Antimicrobial Surveillance Program, 1998 to 2001", Antimicrob Agents Chemother, 47, pp.3989~3993 (2003)
- Moritz VA, "Cefoxitin sensitivity as a marker for inducible beta-lactamases", J Med Microbiol, 21, pp.203~207 (1986)
- Szabo D, "SHV-type extended-spectrum beta-lactamase production is associated with reduced cefepime susceptibility in Enterobacter cloacae", J Clin Microbiol, 43, pp.5058~5064 (2005)
- Wi YM, "Failure of cefepime therapy in neutropenic patients with extended-spectrum beta-lactamase-producing Gram-negative bacteraemia", Int J Antimicrob Agents, 33, pp.384~386 (2009)